Symbols

CGON

CG Oncology·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

Negative Gross Margin

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CGON

Cg Oncology, Inc.

A late-stage clinical biopharmaceutical company focused on treating bladder cancer

Industry

Pharmaceutical

Established Date

09/24/2010

Listing Date

01/25/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

142

Fiscal Year Ends

12-31

Website

cgoncology.com

Security Type

Common stock

Office address

400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618

Business

Introduction

CG Oncology, Inc., a California corporation originally formed on September 24, 2010, was subsequently re-registered as a Delaware corporation on November 30, 2017. The Company is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for the treatment of bladder cancer. Its clinical programs target high-risk and intermediate-risk non-muscle invasive bladder cancer patients with limited treatment options.

Company Financials

EPS

CGON has released its 2025 Q4 earnings. EPS was reported at -0.55, versus the expected -0.6, beating expectations. The chart below visualizes how CGON has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CGON has released its 2025 Q4 earnings report, with revenue of 2.32M, reflecting a YoY change of 409.21%, and net profit of -41.31M, showing a YoY change of -29.91%. The Sankey diagram below clearly presents CGON's revenue sources and cost distribution.